Clinical Trial Update: 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pembrolizumab in combination with bavituximab for squamous cell carcinoma of the head and neck; results posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Bavituximab (bavituximab)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-02-28